hrcak mascot   Srce   HID

Stručni rad

CROATIAN GUIDELINES FOR THE MANAGEMENT OF PANCREATIC EXOCRINE INSUFFICIENCY

Nadan Rustemović
Željko Krznarić
Darija Vranešić Bender
Rajko Ostojić
Silvija Čuković Čavka
Sandra Milić
Branimir Anić
Neven Ljubičić
Jasna Mesarić
Davor Štimac

Puni tekst: hrvatski, pdf (339 KB) str. 0-0 preuzimanja: 190* citiraj
APA 6th Edition
Rustemović, N., Krznarić, Ž., Vranešić Bender, D., Ostojić, R., Čuković Čavka, S., Milić, S., ... Štimac, D. (2012). HRVATSKE SMJERNICE ZA LIJEČENJE EGZOKRINE PANKREASNE INSUFICIJENCIJE. Liječnički vjesnik, 134 (5-6), 0-0. Preuzeto s https://hrcak.srce.hr/172418
MLA 8th Edition
Rustemović, Nadan, et al. "HRVATSKE SMJERNICE ZA LIJEČENJE EGZOKRINE PANKREASNE INSUFICIJENCIJE." Liječnički vjesnik, vol. 134, br. 5-6, 2012, str. 0-0. https://hrcak.srce.hr/172418. Citirano 18.10.2019.
Chicago 17th Edition
Rustemović, Nadan, Željko Krznarić, Darija Vranešić Bender, Rajko Ostojić, Silvija Čuković Čavka, Sandra Milić, Branimir Anić, Neven Ljubičić, Jasna Mesarić i Davor Štimac. "HRVATSKE SMJERNICE ZA LIJEČENJE EGZOKRINE PANKREASNE INSUFICIJENCIJE." Liječnički vjesnik 134, br. 5-6 (2012): 0-0. https://hrcak.srce.hr/172418
Harvard
Rustemović, N., et al. (2012). 'HRVATSKE SMJERNICE ZA LIJEČENJE EGZOKRINE PANKREASNE INSUFICIJENCIJE', Liječnički vjesnik, 134(5-6), str. 0-0. Preuzeto s: https://hrcak.srce.hr/172418 (Datum pristupa: 18.10.2019.)
Vancouver
Rustemović N, Krznarić Ž, Vranešić Bender D, Ostojić R, Čuković Čavka S, Milić S i sur. HRVATSKE SMJERNICE ZA LIJEČENJE EGZOKRINE PANKREASNE INSUFICIJENCIJE. Liječnički vjesnik [Internet]. 2012 [pristupljeno 18.10.2019.];134(5-6):0-0. Dostupno na: https://hrcak.srce.hr/172418
IEEE
N. Rustemović, et al., "HRVATSKE SMJERNICE ZA LIJEČENJE EGZOKRINE PANKREASNE INSUFICIJENCIJE", Liječnički vjesnik, vol.134, br. 5-6, str. 0-0, 2012. [Online]. Dostupno na: https://hrcak.srce.hr/172418. [Citirano: 18.10.2019.]

Sažetak
Pancreatic exocrine insufficiency is a major consequence of pancreatic diseases (e. g. chronic pancreatitis and cystic fibrosis), extrapancreatic diseases like celiac disease and Crohn’s disease, and gastrointestinal and pancreatic surgical resections. Recognition of this entity is highly relevant to avoid malnutrition-related morbidity and mortality. The main clinical consequence of PEI is fat maldigestion and malabsorption, resulting in steatorrhoea. Pancreatic exocrine function should be assessed by measuring levels of faecal elastase-1. Pancreatic enzyme replacement therapy is the mainstay of treatment for PEI. Administration of enzymes in form of enteric-coated minimicrospheres avoids acid-mediated lipase inactivation and ensures gastric emptying of enzymes in parallel with nutrients. In adults, the initial recommended dose of pancreatic enzymes is 25.000 units of lipase per meal, titrating up to a maximum of 80000 units of lipase per meal. Large meals require 25.000 – 80.000 units of lipase per meal while snacks require 10.000 – 40.000 units of lipase per meal. Oral pancreatic enzymes should be taken with meals to ensure adequate mixing with the chyme. Adjunct therapy with acid-suppressing agents may be useful in patients who continue to experience symptoms of PEI despite high-dose enzyme therapy. Patients with PEI should be encouraged to consume small, frequent meals and to abstain from alcohol. Dietary fat restriction is not recommended for patients with PEI.

Ključne riječi
Exocrine pancreatic insufficiency – etiology, complications, therapy; Lipase – therapeutic use, administration and dosage; Enzyme replacement therapy; Practice guidelines as topic; Croatia

Hrčak ID: 172418

URI
https://hrcak.srce.hr/172418

[hrvatski]

Posjeta: 496 *